Amplification Clinical Trials in New York, New York
6 recruitingNew York, New York
Showing 1–6 of 6 trials
Recruiting
Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled42 locationsNCT06995677
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Solid Tumors Harboring MET Amplification
AbbVie100 enrolled33 locationsNCT07196644
Recruiting
Phase 1
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Non-small Cell Lung CancerHER2Advanced Solid Tumor, Adult+3 more
Cogent Biosciences, Inc.100 enrolled6 locationsNCT07361562
Recruiting
Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 1Phase 2
Study of AVZO-021 in Patients With Advanced Solid Tumors
Endometrial CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+6 more
Avenzo Therapeutics, Inc.430 enrolled13 locationsNCT05867251
Recruiting
Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Colorectal, CancerSquamous Cell Carcinoma of Head and NeckHead and Neck Squamous Cell Carcinoma+8 more
Bicara Therapeutics292 enrolled20 locationsNCT04429542